https://www.selleckchem.com/pr....oducts/anlotinib-al3
6; 95% CI, 1.2-5.5) and tumor size 33 mm (HR, 3.9; 95% CI, 2.3-6.7). The specific combination of risk factors contributed to a score for a risk model which classified 9% of Stage I and 69% of Stage ≥II patients as high-risk. The predicted 5-year disease-free survival (DFS) for high-risk and low-risk patients as scored by the predictive model was 30% and 85%, respectively. Our readily reproducible, low-technology model, developed from individually validated tumor/host risk factors, identified sub-groups of resected node-nega
Like
Comment
Share